Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care

Rhea-AI Summary

Oragenics (NYSE American: OGEN) will participate in the SCOPE Summit 2026, Feb 2–5 in Orlando, engaging clinical operations leaders ahead of its planned Phase 2a trial of an intranasal concussion therapeutic in Australia.

The company highlighted its lead candidate ONP-002 and its intranasal delivery platform aimed at targeted, non‑invasive brain delivery for concussion and mild TBI.

Key Figures

Conference edition: 17th annual Conference dates: February 2–5, 2026 Participating companies: over 1,200 companies +1 more

4 metrics

Conference edition 17th annual SCOPE Summit 2026 conference

Conference dates February 2–5, 2026 SCOPE Summit 2026 timing

Participating companies over 1,200 companies Organizations represented at SCOPE Summit 2026

Countries represented 30 countries Geographic reach of SCOPE Summit 2026

Market Reality Check

Price: $0.8408 Vol: Volume 59,019 is 0.06x th...

low vol

$0.8408 Last Close

Volume Volume 59,019 is 0.06x the 20-day average of 916,605, indicating subdued trading ahead of the event. low

Technical Shares at 0.8408 are trading below the 200-day MA at 2.13 and 95.55% below the 52-week high.

Peers on Argus

OGEN was up 2.39% while key biotech peers like XBIO (-5.53%) and QNRX (-14.31%) ...

1 Down

OGEN was up 2.39% while key biotech peers like XBIO (-5.53%) and QNRX (-14.31%) were down, indicating stock-specific dynamics rather than a sector-wide move.

Previous Clinical trial Reports

5 past events · Latest: Jul 31 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jul 31	CRO selection	Positive	-2.3%	Named Southern Star Research as CRO for ONP-002 Phase IIa trial.
Jul 16	Manufacturing deal	Positive	+6.0%	Signed GMP manufacturing agreement with Sterling to support ONP-002 trials.
May 13	HREC approval	Positive	+8.9%	Received HREC approval to begin Phase II concussion trial in Australia.
Apr 09	Ethics submission	Positive	+6.7%	Submitted Phase IIa protocol to New Zealand HDEC for ONP-002 trial.
Mar 06	IB submission	Positive	-0.9%	Filed Investigator’s Brochure for Phase II ONP-002 mTBI trial in Australia.

Pattern Detected

Clinical-trial news for ONP-002 has more often led to positive price reactions, though there are instances of negative divergence.

Recent Company History

Over the last year, Oragenics has advanced ONP-002 through key clinical milestones, from the IB submission in March 2025 to ethics approvals and site selections across Australia and New Zealand. Clinical trial updates on May 13, April 9, and July 16, 2025 produced price gains, while two events (Mar 06 and Jul 31, 2025) saw modest declines. Today’s SCOPE Summit participation reinforces the ongoing Phase II development narrative rather than introducing a new clinical inflection point.

Historical Comparison

clinical trial

+5.0 %

Average Historical Move

Historical Analysis

Clinical-trial updates on ONP-002 have averaged a 4.96% move. This conference-focused update is more incremental, fitting the ongoing Phase IIa build-out narrative.

Typical Pattern

Historical clinical-trial news shows a progression from IB submission to ethics approvals, CRO and manufacturing deals, and now conference participation as ONP-002 advances toward Phase IIa/IIb concussion studies.

Regulatory & Risk Context

Active S-3 Shelf · $100,000,000

Shelf Active

Active S-3 Shelf Registration 2026-01-22

$100,000,000 registered capacity

An effective Form S-3 shelf filed on Jan 22, 2026 would permit Oragenics to offer up to $100,000,000 of securities, including $34,156,040 carried over from a prior shelf. As of Jan 21, 2026, the public float was about $4,222,535, and primary offerings under this shelf are limited to one-third of that float in any twelve-month period unless the float reaches $75.0 million.

Market Pulse Summary

This announcement highlights Oragenics’ participation in SCOPE Summit 2026, a major clinical-operati...

Analysis

This announcement highlights Oragenics’ participation in SCOPE Summit 2026, a major clinical-operations conference drawing leaders from over 1,200 companies across 30 countries. It reinforces the narrative that ONP-002 is advancing toward Phase 2a concussion trials using an intranasal delivery platform. In context of prior ethics approvals and CRO/manufacturing agreements, investors may watch for concrete milestones such as trial initiation timelines, enrollment progress, and future regulatory updates tied to these Phase II studies.

Key Terms

phase 2a, clinical-stage biotechnology, intranasal therapeutics, mild traumatic brain injury, +2 more

6 terms

phase 2a medical

"ahead of Phase 2a Trial of Concussion Treatment"

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

clinical-stage biotechnology medical

"a clinical-stage biotechnology company focused on developing intranasal therapeutics"

Clinical-stage biotechnology refers to biotechnology companies that are in the process of testing new medical treatments or drugs in human trials. This stage is crucial because it indicates that these treatments have shown enough promise in earlier research to be evaluated for safety and effectiveness in people. For investors, it signals a key phase where potential breakthroughs are being tested, but also involves higher risk since the outcomes are still uncertain.

intranasal therapeutics medical

"focused on developing intranasal therapeutics for neurological disorders"

Medications or vaccines formulated to be given through the nose so the active ingredient is absorbed across the nasal lining into the bloodstream or, in some cases, directly to the brain. For investors, intranasal delivery can mean faster onset, easier use and better patient acceptance compared with injections, which can boost market adoption or create distinct regulatory and manufacturing challenges that affect commercial value—like swapping a shot for a spray.

mild traumatic brain injury medical

"treatment for concussion and mild traumatic brain injury—conditions with significant unmet"

A mild traumatic brain injury (mTBI), often called a concussion, is a short-lived disturbance in brain function caused by a blow, jolt, or sudden movement of the head that can produce headaches, dizziness, memory problems or brief loss of consciousness. Investors watch mTBI because it drives demand for diagnostics, treatments and rehabilitation, influences potential legal and insurance costs, and can affect healthcare spending, product approval prospects and company valuations in medical and sports-related sectors.

cros technical

"senior executives from pharma, biotech, CROs, sites, technology, investment,"

Contract research organizations (CROs) are independent firms hired by drug and medical-device companies to run research tasks such as clinical trials, patient recruitment, lab testing, data management, and regulatory filings. For investors they matter because CROs act like contractors turning a sponsor’s plans into finished work—so their capacity, timelines, costs and quality directly affect how quickly and cheaply a drug or device can move toward approval and revenue.

generative ai technical

"topics like development planning, protocol optimization, patient-centric trial design... generative AI, small biopharma"

Generative AI is a type of computer technology that can create new content, like text, images, or music, on its own. It’s important because it can produce realistic and useful material quickly, which could change how we create art, write stories, or even develop new products. Think of it as a smart robot that can invent and produce things almost like a human.

AI-generated analysis. Not financial advice.

Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment

Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced its participation at the SCOPE Summit 2026, the 17^th annual conference organized by the Cambridge Healthtech Institute. SCOPE (Summit for Clinical Ops Executives) is a clinical research conference being held February 2–5, 2026, in Orlando, Florida.

“Oragenics is excited to participate in one of the premier global conferences for clinical operations and optimal trial execution — a timely event as we approach the Phase 2a clinical trial of our first-of-its-kind concussion therapeutic in Australia,” said Janet Huffman, Chief Executive Officer. “We look forward to engaging with experts from biopharma, scientific research, and regulatory affairs at SCOPE, especially the technology innovators advancing medical progress and bolstering the body of scientific knowledge.”

Oragenics is working towards advancing neurological care through its proprietary intranasal delivery platform designed to enable targeted, non-invasive delivery of therapeutics directly to the brain. Its lead candidate, ONP-002, is advancing toward Phase 2a clinical trials in Australia with the goal of developing it as a treatment for concussion and mild traumatic brain injury—conditions with significant unmet medical need and no FDA-approved therapies.

The SCOPE Summit welcomes senior executives from pharma, biotech, CROs, sites, technology, investment, and patient advocacy organizations, representing over 1,200 companies across 30 countries. The 2026 program will cover in-demand topics like development planning, protocol optimization, patient-centric trial design, site engagement and recruitment, generative AI, small biopharma strategies, RBQM, supply and clintech investment—all focused on advancing solutions in trial planning, operations, innovation, and investment. Visit scopesummit.com for more information.

About Oragenics, Inc.

Oragenics, Inc. is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The Company is working on advancing its lead candidate, ONP-002, as a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics is working on commencing clinical trials in Australia for ONP-002 , with U.S. Phase 2b trials planned to follow. The Company's intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. Oragenics is committed to developing innovative therapies that address significant unmet medical needs in neurological care. For more information, visit oragenics.com.

Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our future performance, business prospects, expectations and product development plans. These forward-looking statements are not historical facts, but are based on current expectations, estimates and projections about our industry, our beliefs and our assumptions. These forward-looking statements include statements about our strategies, objectives, beliefs, goals, and expectations, including those concerning, among other things, our research, development and regulatory activities, our product development timelines, our future products, regulatory matters, our expectations relating to our products candidates, including ONP-002, the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of concussion and mild traumatic brain injury, and the timing, conduct, interim results announcements and outcomes of our clinical trials of our product candidates, including ONP-002.These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project," "potential," "may," "will," "could," "should," and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our most recent Form 10-K, Form 10-Q and other filings we make with the U.S. Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. All information we set forth in this press release is as of the date hereof. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, except as otherwise required by law.

Investor Contact:
800-383-4880
ir@oragenics.com

FAQ

What will Oragenics (OGEN) discuss at SCOPE Summit 2026 on February 2–5?

Oragenics will engage clinical operations and regulatory experts about trial execution and intranasal delivery strategies. According to the company, discussions will focus on protocol optimization, site engagement, patient‑centric design, and technologies relevant to its upcoming Phase 2a concussion trial in Australia.

How does Oragenics describe ONP-002 and its status (OGEN)?

ONP-002 is described as an intranasal therapeutic advancing toward Phase 2a clinical trials in Australia. According to the company, the program targets concussion and mild traumatic brain injury where no FDA‑approved therapies currently exist.

Why is Oragenics (OGEN) attending SCOPE Summit before its Phase 2a trial?

Oragenics is attending to connect with biopharma, CROs, and regulators to refine trial design and operations. According to the company, engagement aims to improve recruitment, protocol optimization, and logistics ahead of the planned Australian Phase 2a study.

Will Oragenics (OGEN) present clinical data at SCOPE Summit 2026?

The company announced participation but did not state a data presentation or poster at the summit. According to the company, planned activities emphasize operational engagement and technology discussions rather than releasing new clinical readouts at the event.

How can investors learn more about Oragenics' (OGEN) SCOPE Summit participation and ONP-002 timeline?

Investors can monitor company communications and investor channels for updates on trial milestones and presentations. According to the company, SCOPE participation is part of preparatory engagement ahead of the Phase 2a trial in Australia; further timelines will be announced by the company.